Tomkinson
Adrian Tomkinson, El Cerrito, CA US
Patent application number | Description | Published |
---|---|---|
20090010874 | MODIFIED IL-4 MUTEIN RECEPTOR ANTAGONISTS - This invention relates to modified IL-4 mutein receptor antagonists comprising an IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and dosages and methods of administration thereof for therapeutic purposes are also provided. These modified IL-4 mutein receptor antagonists, compositions and methods provide a treatment option for those individuals afflicted with a respiratory disorder such as asthma by inhibiting IL-4 and IL-13-mediated airway hyperresponsiveness and eosinophilia. More particularly, these antagonists have an increased duration of effect versus unmodified IL-4RA by virtue of a greater plasma half-life. | 01-08-2009 |
20110158939 | Methods and Compositions for Treating Asthma in Human and Nonhuman Primates - The present invention relates generally to methods and compounds for treating pulmonary disorders, and more specifically to the inhalation administration and use of hIL-4 mutant proteins to treat asthma. | 06-30-2011 |
20110183920 | MODIFIED IL-4 MUTEIN RECEPTOR ANTAGONISTS - This invention relates to modified IL-4 mutein receptor antagonists comprising an IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and dosages and methods of administration thereof for therapeutic purposes are also provided. These modified IL-4 mutein receptor antagonists, compositions and methods provide a treatment option for those individuals afflicted with a respiratory disorder such as asthma by inhibiting IL-4 and IL-13-mediated airway hyperresponsiveness and eosinophilia. More particularly, these antagonists have an increased duration of effect versus unmodified IL-4RA by virtue of a greater plasma half-life. | 07-28-2011 |
Alan E. Tomkinson, Albuquerque, NM US
Patent application number | Description | Published |
---|---|---|
20140113891 | Compounds that inhibit human DNA ligases and methods of treating cancer - Methods for treating cancer using compounds that inhibit human DNA ligases. Methods for using compounds that inhibit human DNA ligases to provide insights into the reaction mechanisms of human DNA ligases, for example to identify the human DNA ligase involved in different DNA repair pathways. Screening methods for compounds that inhibit human DNA ligases. | 04-24-2014 |
20150313898 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER - Methods for treating cancer using compounds that inhibit human DNA ligases. Methods for using compounds that inhibit human DNA ligases to provide insights into the reaction mechanisms of human DNA ligases, for example to identify the human DNA ligase involved in different DNA repair pathways. Screening methods for compounds that inhibit human DNA ligases. | 11-05-2015 |
Alan E. Tomkinson, Glenwood, MD US
Patent application number | Description | Published |
---|---|---|
20100099683 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER - Methods for treating cancer using compounds that inhibit human DNA ligases. Methods for using compounds that inhibit human DNA ligases to provide insights into the reaction mechanisms of human DNA ligases, for example to identify the human DNA ligase involved in different DNA repair pathways. Screening methods for compounds that inhibit human DNA ligases. | 04-22-2010 |
Alan Edward Tomkinson, Albuquerque, NM US
Patent application number | Description | Published |
---|---|---|
20160051517 | TARGETING ABNORMAL DNA REPAIR IN THERAPY-RESISTANT BREAST AND PANCREATIC CANCERS - In one embodiment, the invention provides a method of treating a subject suffering from a breast cancer tumor which is non-responsive or intrinsically resistant to anti-estrogen therapy comprising administering a therapeutically effective amount of an inhibitor of alternative (ALT) non-homologous end joining (NHEJ) factor to the subject. | 02-25-2016 |
Blake Tomkinson, Weston, MA US
Patent application number | Description | Published |
---|---|---|
20150118251 | SPECIFIC ANTI-CD38 ANTIBODIES FOR TREATING HUMAN CANCERS - The present disclosure concerns an antibody that specifically binds CD38 which is capable of killing a CD38 | 04-30-2015 |
Blake Tomkinson, Bridgewater, NJ US
Patent application number | Description | Published |
---|---|---|
20140161819 | Compositions Comprising Anti-CD38 Antibodies and Lenalidomide - Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and lenalidomide compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits. | 06-12-2014 |
20160022813 | COMPOSITIONS COMPRISING ANTI-CD38 ANTIBODIES AND CARFILZOMIB - Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and carfilzomib compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits. | 01-28-2016 |
Gary Peter Tomkinson, Macclesfield GB
Patent application number | Description | Published |
---|---|---|
20100184813 | CHEMICAL COMPOUNDS 553 - DGAT-1 inhibitor compounds of formula (I) and pharmaceutically-acceptable salts thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity | 07-22-2010 |
20100278835 | NOVEL COMPOUNDS 660 - The invention provides compounds of formula (I) | 11-04-2010 |
20110028529 | NOVEL CRYSTALLINE FORMS OF 4-[4-(2-ADAMANTYLCARBAMOYL)-5-TERT-BUTYL-PYRAZOL-1-YL]BENZOIC ACID 471 - New crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described. | 02-03-2011 |
20110028530 | NOVEL CRYSTALLINE FORMS OF 4-[4-(2-ADAMANTYLCARBAMOYL)-5-TERT-BUTYL-PYRAZOL-1-YL]BENZOIC ACID 471 - New crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described. | 02-03-2011 |
20150087661 | Crystalline Forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]py- rimidin-4-yl) piperidine-4-carboxamide - The present invention discloses certain new solid state forms of (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide, processes for preparing such forms, pharmaceutical compositions comprising them, and the use of such forms in therapy. | 03-26-2015 |
Gary Peter Tomkinson, Cheshire GB
Patent application number | Description | Published |
---|---|---|
20090221660 | NOVEL CRYSTALLINE FORMS OF 4-[4-(2-ADAMANTYLCARBAMOYL)-5-TERT-BUTYL-PYRAZOL-1-YL]BENZOIC ACID 471 - New crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described. | 09-03-2009 |
20100094009 | NOVEL CRYSTALLINE COMPOUND USEFUL AS GLK ACTIVATOR - A novel crystalline form of 3-{[5-(azetidin-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-[(1-methylethyl)oxy]-N-1H-pyrazol-3-ylbenzamide is described in the specification. This compound is a glucokinase (GLK or GK) activator and useful as a pharmaceutical agent in the treatment or prevention of a disease or medical condition mediated through GLK, leading to a decreased glucose threshold for insulin secretion. Processes for the manufacture of the crystalline form, pharmaceutical compositions comprising the crystalline form and the use of the crystalline form in medical treatment are also described. | 04-15-2010 |
20140206700 | CHEMICAL COMPOUNDS - The invention concerns compounds of Formula (I) | 07-24-2014 |
Kathleen N. Tomkinson, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20100305194 | MODIFIED AND STABILIZED GDF PROPEPTIDES AND USES THEREOF - Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the modified propeptides to prevent or treat human or animal disorders in which an increase in muscle tissue would be therapeutically beneficial. Such disorders include muscle or neuromuscular disorders (such as amyotrophic lateral sclerosis, muscular dystrophy, muscle atrophy, congestive obstructive pulmonary disease, muscle wasting syndrome, sarcopenia, or cachexia), metabolic diseases or disorders (such as such as type 2 diabetes, noninsulin-dependent diabetes mellitus, hyperglycemia, or obesity), adipose tissue disorders (such as obesity), and bone degenerative diseases (such as osteoporosis). | 12-02-2010 |
20120252884 | Modified and Stabilized GDF Propeptides and Uses Thereof - Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the modified propeptides to prevent or treat human or animal disorders in which an increase in muscle tissue would be therapeutically beneficial. Such disorders include muscle or neuromuscular disorders (such as amyotrophic lateral sclerosis, muscular dystrophy, muscle atrophy, congestive obstructive pulmonary disease, muscle wasting syndrome, sarcopenia, or cachexia), metabolic diseases or disorders (such as such as type 2 diabetes, noninsulin-dependent diabetes mellitus, hyperglycemia, or obesity), adipose tissue disorders (such as obesity), and bone degenerative diseases (such as osteoporosis). | 10-04-2012 |
Nicholas Tomkinson, Leicestershire GB
Patent application number | Description | Published |
---|---|---|
20090305321 | Assays for Allosteric Modulators of G-Protein Coupled Receptors (GPCRs) - The present invention relates to G protein-coupled receptors (GPCRs) and allosteric modulators thereof. More specifically, the invention relates to allosteric modulators of GPCRs that interact at an intracellular binding site. It also relates to methods for designing or identifying small molecule allosteric modulators, including assays (such as competitive binding assays) and methods employing a homology model for the GPCR intracellular site. | 12-10-2009 |
Roger Kenyon Tomkinson, Towcester GB
Patent application number | Description | Published |
---|---|---|
20110162828 | THERMAL PLUG FOR USE WITH A HEAT SINK AND METHOD OF ASSEMBLING SAME - A plug is provided for use with a heat sink body and an electronic device. The plug includes a first plug member and a second plug member. The first plug member defines a socket therein. The second plug member is movable within the socket such that a bottom surface of the second plug member is maintained in a substantially parallel position with respect to a top surface of the electronic device. | 07-07-2011 |
Shane Ashley Tomkinson, Timaru NZ
Patent application number | Description | Published |
---|---|---|
20160116032 | MECHANISM FOR CONVERTING MOTION - A mechanism | 04-28-2016 |
Todd Harding Tomkinson, Newbury Park, CA US
Patent application number | Description | Published |
---|---|---|
20090147341 | Coherence Length Controller - Techniques for producing higher fidelity interferometer measurements by reducing sensitivity to spurious sources include reducing the coherence length of an electromagnetic beam. In addition, multiple surfaces within an optical system may be measured by electronically tuning the position of a coherence plane along the optical paths of an interferometer. A phase modulator is used in conjunction with a long coherence length electromagnetic source to generate beams for each leg of an interferometer. Providing a controlled broadband RF signal to the phase modulator increases the bandwidth of the beam and thereby reduces the coherence length of the beam. This reduces the spurious contributions to the output interference fringes from undesired surfaces along the beam path. | 06-11-2009 |